Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
ABSTRACT Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible treatment regimens compatible with backgro...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70223 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309326912520192 |
|---|---|
| author | Ahsan Rizwan Hugh Giovinazzo Tian Yu Yuying Gao Kun Wang Fengyan Xu Ya Wan Jun Wang Srikumar Sahasranaman Marcia Campbell Patrick Schnell Ramil Abdrashitov William D. Hanley Nageshwar Budha |
| author_facet | Ahsan Rizwan Hugh Giovinazzo Tian Yu Yuying Gao Kun Wang Fengyan Xu Ya Wan Jun Wang Srikumar Sahasranaman Marcia Campbell Patrick Schnell Ramil Abdrashitov William D. Hanley Nageshwar Budha |
| author_sort | Ahsan Rizwan |
| collection | DOAJ |
| description | ABSTRACT Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible treatment regimens compatible with background chemotherapy and/or reducing infusion visits. A previously developed population pharmacokinetic model was used to simulate pharmacokinetic exposure of the alternative regimens. Regulatory guidance on alternative dosing was used to define pharmacokinetics‐based criteria. Alternative doses were selected by simulation, exposure matching, and comparison to the reference regimen of 200 mg Q3W. Deviations from pharmacokinetics‐based criteria were bridged using appropriate safety and efficacy references and exposure–response analyses. All three alternative dosing regimens produced comparable exposures versus 200 mg Q3W. Although simulated peak serum concentration (Cmax) at 300 mg Q4W and 400 mg Q6W was higher versus 200 mg Q3W, this was below the Cmax of the 5 mg/kg Q3W safety reference. And while the trough serum concentration (Ctrough) for 400 mg Q6W was slightly lower versus 200 mg Q3W, it was 10.7% higher than the 2 mg/kg efficacy reference Ctrough, and therefore, within the concentration range in which a flat exposure–efficacy relationship of tislelizumab has been established. Tislelizumab regimens of 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W are expected to result in similar safety and efficacy as 200 mg Q3W. |
| format | Article |
| id | doaj-art-4d8a4b193fdc4ec6b922871de526b9ec |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-4d8a4b193fdc4ec6b922871de526b9ec2025-08-20T03:54:11ZengWileyClinical and Translational Science1752-80541752-80622025-05-01185n/an/a10.1111/cts.70223Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based ApproachAhsan Rizwan0Hugh Giovinazzo1Tian Yu2Yuying Gao3Kun Wang4Fengyan Xu5Ya Wan6Jun Wang7Srikumar Sahasranaman8Marcia Campbell9Patrick Schnell10Ramil Abdrashitov11William D. Hanley12Nageshwar Budha13Clinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USAClinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USAClinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USAPharmacometrics Shanghai Qiangshi Information Technology Co., Ltd. Shanghai ChinaPharmacometrics Shanghai Qiangshi Information Technology Co., Ltd. Shanghai ChinaPharmacometrics Shanghai Qiangshi Information Technology Co., Ltd. Shanghai ChinaScientific Programming BeiGene (Shanghai) Co., Ltd. Shanghai ChinaGlobal Statistics and Data Sciences BeiGene (Beijing), Co., Ltd. Beijing ChinaClinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USARegulatory Affairs BeiGene (Canada) ULC Toronto Ontario CanadaProduct Safety BeiGene USA, Inc. Ridgefield New Jersey USAClinical Development BeiGene USA, Inc. Fulton Maryland USAClinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USAClinical Pharmacology and Pharmacometrics BeiGene USA, Inc. San Carlos California USAABSTRACT Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible treatment regimens compatible with background chemotherapy and/or reducing infusion visits. A previously developed population pharmacokinetic model was used to simulate pharmacokinetic exposure of the alternative regimens. Regulatory guidance on alternative dosing was used to define pharmacokinetics‐based criteria. Alternative doses were selected by simulation, exposure matching, and comparison to the reference regimen of 200 mg Q3W. Deviations from pharmacokinetics‐based criteria were bridged using appropriate safety and efficacy references and exposure–response analyses. All three alternative dosing regimens produced comparable exposures versus 200 mg Q3W. Although simulated peak serum concentration (Cmax) at 300 mg Q4W and 400 mg Q6W was higher versus 200 mg Q3W, this was below the Cmax of the 5 mg/kg Q3W safety reference. And while the trough serum concentration (Ctrough) for 400 mg Q6W was slightly lower versus 200 mg Q3W, it was 10.7% higher than the 2 mg/kg efficacy reference Ctrough, and therefore, within the concentration range in which a flat exposure–efficacy relationship of tislelizumab has been established. Tislelizumab regimens of 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W are expected to result in similar safety and efficacy as 200 mg Q3W.https://doi.org/10.1111/cts.70223alternative doseanti–PD‐1exposure–responseimmunotherapypharmacokineticspharmacometrics |
| spellingShingle | Ahsan Rizwan Hugh Giovinazzo Tian Yu Yuying Gao Kun Wang Fengyan Xu Ya Wan Jun Wang Srikumar Sahasranaman Marcia Campbell Patrick Schnell Ramil Abdrashitov William D. Hanley Nageshwar Budha Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach Clinical and Translational Science alternative dose anti–PD‐1 exposure–response immunotherapy pharmacokinetics pharmacometrics |
| title | Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach |
| title_full | Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach |
| title_fullStr | Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach |
| title_full_unstemmed | Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach |
| title_short | Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach |
| title_sort | alternative dosing regimens of tislelizumab using a pharmacometrics model based approach |
| topic | alternative dose anti–PD‐1 exposure–response immunotherapy pharmacokinetics pharmacometrics |
| url | https://doi.org/10.1111/cts.70223 |
| work_keys_str_mv | AT ahsanrizwan alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT hughgiovinazzo alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT tianyu alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT yuyinggao alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT kunwang alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT fengyanxu alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT yawan alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT junwang alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT srikumarsahasranaman alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT marciacampbell alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT patrickschnell alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT ramilabdrashitov alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT williamdhanley alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach AT nageshwarbudha alternativedosingregimensoftislelizumabusingapharmacometricsmodelbasedapproach |